ANDA 76723, held by Mpp Pharma. Hydromorphone Hydrochloride.
As of Nov 16, 2026, ANDA 76723 (Hydromorphone Hydrochloride), held by Mpp Pharma, was first approved by FDA on Oct 18, 2005, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 18, 2005 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydromorphone Hydrochloride8MG · tablet;oral | Hydromorphone Hydrochloride | Discontinued |
| Oct 31, 2024 | Supplement 12REMS | Approved | None posted |
| Apr 15, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 15, 2020 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 15, 2020 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 15, 2020 | Supplement 11Labeling · Standard review | Approved | None posted |
| Sep 18, 2018 | Supplement 8REMS | Approved | None posted |
| Oct 18, 2005 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters